


(19)  **Europäisches Patentamt**  
**European Patent Office**  
**Office européen des brevets**



(11) **EP 1 227 107 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
**31.07.2002 Bulletin 2002/31**

(51) Int Cl.7: **C07K 14/62**

(21) Application number: **02000258.0**

(22) Date of filing: **14.11.1995**

(84) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE**  
 Designated Extension States:  
**LT LV SI**

(30) Priority: **17.11.1994 US 341231**

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:  
**95308167.6 / 0 712 862**

(71) Applicant: **ELI LILLY AND COMPANY**  
**Indianapolis, Indiana 46285 (US)**

(72) Inventors:  
 • **Baker, Jeffrey Clayton**  
**Indianapolis, Indiana 46205 (US)**  
 • **Chen, Victor John**  
**Indianapolis, Indiana 46140 (US)**

- **Kriauciunas, Aidas Vladas**  
**Indianapolis, Indiana 46254 (US)**
- **Moser, Brian Alden**  
**Indianapolis, Indiana 46217 (US)**
- **Hanqueler, Jose Michael**  
**Martinsville, Indiana 46151 (US)**
- **Shuman, Robert Theodore**  
**Greenwood, Indiana 46143 (US)**

(74) Representative: **Pritchard, Judith et al**  
**Eli Lilly and Company Limited**  
**Lilly Research Centre**  
**Erl Wood Manor**  
**Windlesham, Surrey GU20 6PH (GB)**

Remarks:  
 This application was filed on 15 - 01 - 2002 as a divisional application to the application mentioned under INID code 62.

(54) **Selective acylation of E-amino groups**

(57) The present invention relates to the acylation of proteins. More particularly, the invention relates to a one-step process for selectively acylating the free  $\epsilon$ -amino group of insulin, insulin analog, or proinsulin in the presence of a free  $\alpha$ -amino group.

EP 1 227 107 A1

## Description

- [0001] The present invention relates to the acylation of proteins. More particularly, the invention relates to a one-step process for selectively acylating the  $\epsilon$ -amino group of proinsulin, insulin or an insulin analog in the presence of a free  $\alpha$ -amino group.
- [0002] The acylation of amino groups is one of the most common means employed for chemically modifying proteins. General methods of acylation are set forth in Methods of Enzymology, 25: 494-499 (1972) and include the use of activated esters, acid halides, or acid anhydrides. The use of activated esters, in particular N-hydroxysuccinimide esters of fatty acids is a particularly advantageous means of acylating a free amino acid with a fatty acid. Lapidot et al., J. of Lipid Res. 8: 142-145 (1967). Lapidot et al. describe the preparation of N-hydroxysuccinimide esters and their use in the preparation of N-lauroyl-glycine, N-lauroyl-L-serine, and N-lauroyl-L-glutamic acid.
- [0003] Early studies of selectively acylating the amino groups of insulin are described in Lindsay et al., in Biochem. J. 121: 737-745 (1971). Lindsay et al., describe the reactivity of insulin with N-succinimidyl acetate at low reagent concentration and near neutral pH as producing two mono-substituted products, Phe<sup>B1</sup>-acetyl-insulin and Gly<sup>A1</sup>-acetyl insulin. At pH 8.5, the amount of Phe<sup>B1</sup>-acetyl insulin produced is lowered and Lys<sup>B29</sup>-acetyl-insulin is also produced. Thus, Lindsay et al., conclude at pH 6.9 the order of reactivity is Glycine(A1)•Phenylalanine(B1)>>Lysine(B29) and at pH 8.5 Glycine(A1)>Phenylalanine•Lysine(B29). Id.
- [0004] Lindsay et al., U.S. Patent 3,869,437, disclose the acylation of the B<sup>1</sup> amino acid with an acyl group containing up to seven carbons and optionally blocking the A<sup>1</sup>- and/or B<sup>29</sup>-amino group with an acyl group with up to four carbons. N-hydroxysuccinimide esters are described as particularly advantageous acylating agents. In order to produce the maximum yield of insulin acylated at the B<sup>1</sup>-amino group, the proportion of acylating agent is relatively low (one to not more than two molar equivalents of acylating agent). In addition, the maximum yield of mono-substituted B<sup>1</sup> product is produced at a pH at or near about pH 7. At pH 8.5 to 9.0, the yield of the desired B<sup>1</sup> acylated product falls off considerably in favor of additional substitution at positions A<sup>1</sup> and B<sup>29</sup>.
- [0005] D.G. Smyth, in U.S. patent 3,868,356 and Smyth et al., in U.S. patent 3,868,357 disclose N-acylated, O-substituted insulin derivatives in which at least one of the A<sup>1</sup>, B<sup>1</sup> or B<sup>29</sup> amino acid amino groups is converted into a blocked amino group. The acylation is carried out with a relatively small excess of acylating agent, e.g., from 2 to 3 moles per amino group at a neutral or mildly alkaline pH, e.g., 7-8. The reaction proceeds in very high yield with the formation of the di-substituted derivative resulting from the reaction of the A<sup>1</sup>- and B<sup>1</sup>- amino groups. In the presence of excess acylating agent, e.g., up to 10 molar, the reaction proceeds additionally at the B<sup>29</sup>- amino group to form the tri-substituted derivative.
- [0006] To selectively acylate insulin, Muranishi and Kiso, in Japanese Patent Application 1-254,699, disclose a five-step synthesis for preparing fatty acid insulin derivatives. Step one, the activated fatty acid ester is prepared; Step two, the amino groups of insulin are protected with p-methoxy benzoxy carbonylazide (pMZ); Step three, the insulin-pMZ is reacted with the fatty acid ester; Step four, the acylated insulin is deprotected; and Step five, the acylated insulin is isolated and purified. Most notably, selective acylation of one amino group is only achieved by using the pMZ blocking group to protect the other amino groups. Using this methodology, Muranishi and Kiso prepare the following compounds: Lys<sup>B29</sup>-palmitoyl insulin (the  $\epsilon$ -amino group is acylated), Phe<sup>B1</sup>-palmitoyl insulin (the N terminal  $\alpha$ -amino group of the B chain is acylated), and Phe<sup>B1</sup>,Lys<sup>B29</sup>- dipalmitoyl insulin (both the  $\epsilon$ -amino and the N-terminal  $\alpha$ -amino group are acylated).
- [0007] Similarly, Hashimoto et al., in Pharmaceutical Research 6: 171-176 (1989), teach a four step synthesis for preparing N-palmitoyl insulin. The synthesis includes protecting and deprotecting the N-terminal A<sup>1</sup>-glycine and the  $\epsilon$ -amino group of B<sup>29</sup>-lysine, with pMZ. Under the conditions described in the reference, two major acylated products are prepared, B<sup>1</sup>-mono-palmitoyl insulin and B<sup>1</sup>,B<sup>29</sup>-dipalmitoyl insulin.
- [0008] Therefore, prior to the present invention, the selective acylation of the B<sup>29</sup>-N $\epsilon$ -amino group of insulin was carried out by protecting and subsequently deprotecting the  $\alpha$ -amino groups.
- [0009] The present invention provides a selective one-step synthesis for acylating the  $\epsilon$ -amino group of proinsulin, insulin and insulin analogs. It is quite surprising that the invention is able to selectively acylate the  $\epsilon$ -amino group in an one step process in high yield. Thus, the invention eliminates the need to protect and subsequently deprotect other amino groups of the protein. The invention provides more efficient and less expensive means of preparing  $\epsilon$ -amino acylated insulin derivatives.
- [0010] The present invention provides a process of selectively acylating proinsulin, insulin, or an insulin analog having a free  $\epsilon$ -amino group and a free  $\alpha$ -amino group with a fatty acid, which comprises reacting the  $\epsilon$ -amino group with a soluble activated fatty acid ester under basic conditions in a polar solvent.
- [0011] All amino acid abbreviations used in this disclosure are those accepted by the United States Patent and Trademark Office as set forth in 37 C.F.R. § 1.822 (B) (2).
- [0012] As noted above, the present invention provides a highly selective, one step acylation of the  $\epsilon$ -amino group of proinsulin, insulin or an insulin analog. The invention specifies conditions that preferentially acylate the  $\epsilon$ -amino group

over the  $\alpha$ -amino groups. Generally, the mono-acylated  $\alpha$ -amino group is produced in less than 5% yield.

[0013] The term "insulin" as used herein means human insulin, pork insulin, or beef insulin. Insulin possesses three free amino groups: B<sup>1</sup>-Phenylalanine, A<sup>1</sup>-Glycine, and B<sup>29</sup>-Lysine. The free amino groups at positions A<sup>1</sup> and B<sup>1</sup> are  $\alpha$ -amino groups. The free amino group at position B<sup>29</sup> is an  $\epsilon$ -amino group.

[0014] The term "proinsulin" as used herein is a properly cross-linked protein of the formula:



wherein:

A is the A chain of insulin or a functional derivative thereof;

B is the B chain of insulin or a functional derivative thereof having an  $\epsilon$ -amino group; and

C is the connecting peptide of proinsulin. Preferably, proinsulin is the A chain of human insulin, the B chain of human insulin, and C is the natural connecting peptide. When proinsulin is the natural sequence, proinsulin possesses three free amino groups: B<sup>1</sup>-Phenylalanine ( $\alpha$ -amino group), C<sup>64</sup>-Lysine ( $\epsilon$ -amino group) and B<sup>29</sup>-Lysine ( $\epsilon$ -amino group).

[0015] The term "insulin analog" as used herein is a properly cross-linked protein of the formula:



wherein:

A is a functional derivative of the insulin A chain; and

B is a functional derivative of the insulin B chain having an  $\epsilon$ -amino group.

[0016] Preferred insulin analogs include insulin wherein:

the amino acid residue at position B<sup>28</sup> is Asp, Lys, Leu, Val, or Ala;

the amino acid residue at position B<sup>29</sup> is Lys or Pro;

the amino acid residue at position B<sup>10</sup> is His or Asp;

the amino acid residue at position B<sup>1</sup> is Phe, Asp, or deleted alone or in combination with a deletion of the residue at position B<sup>2</sup>;

the amino acid residue at position B<sup>30</sup> is Thr, Ala, or deleted; and

the amino acid residue at position B<sup>9</sup> is Ser or Asp;

provided that either position B<sup>28</sup> or B<sup>29</sup> is Lys.

[0017] In standard biochemical terms known to the ordinarily skilled artisan the preferred insulin analogs are Lys<sup>B28</sup>Pro<sup>B29</sup>-human insulin (B<sup>28</sup> is Lys; B<sup>29</sup> is Pro); Asp<sup>B28</sup>-human insulin (B<sup>28</sup> is Asp); Asp<sup>B1</sup>-human insulin, Arg<sup>B31</sup>B<sup>B32</sup>-human insulin, Asp<sup>B10</sup>-human insulin, Arg<sup>A0</sup>-human insulin, Asp<sup>B1</sup>Glu<sup>B13</sup>-human insulin, Ala<sup>B26</sup>-human insulin, des(B30)-human insulin, and Gly<sup>A21</sup>-human insulin.

[0018] The term "acylating" means the introduction of one or more acyl groups covalently bonded to the free amino groups of the protein.

[0019] The term "selective acylation" means the preferential acylation of the  $\epsilon$ -amino group(s) over the  $\alpha$ -amino groups. Generally, selective acylation results in a ratio of the amount of mono-acylated  $\epsilon$ -amino group product to mono-acylated  $\alpha$ -amino group product greater than about 5. Preferably, the ratio is greater than about 10, and most preferably greater than about 50.

[0020] The term "fatty acid" means a saturated or unsaturated C<sub>6</sub>-C<sub>21</sub> fatty acid. The term "activated fatty acid ester" means a fatty acid which has been activated using general techniques described in Methods of Enzymology, 25, 494-499 (1972) and Lapidot et al., in J. of Lipid Res. 8: 142-145 (1967). The preferred fatty acids are saturated and include myristic acid (C<sub>14</sub>), pentadecylic acid (C<sub>15</sub>), palmitic acid (C<sub>16</sub>), heptadecylic acid (C<sub>17</sub>) and stearic acid (C<sub>18</sub>). Most preferably, the fatty acid is palmitic acid. Activated fatty acid ester includes derivatives of agents such as hydroxy-benzotriazide (HOBt), N-hydroxysuccinimide and derivatives thereof. The preferred activated ester is N-succinimidyl palmitate.

[0021] The term "soluble" indicates that a sufficient amount of ester is present in the liquid phase to acylate the insulin, insulin analog or proinsulin. Preferably, about 1 to 4 molar equivalents of activated ester per mole of insulin

are in the liquid phase.

[0022] The term "basic conditions" as used herein refers to the basicity of the reaction. The reaction must be carried out with all the free amino groups substantially deprotonated. In an aqueous solvent or semi-aqueous solvent mixture, basic conditions means the reaction is carried out at a pH greater than 9.0. In a non-aqueous organic solvent, the reaction is carried out in the presence of a base with basicity equivalent to a  $pK_a$  greater than or equal to 10.75 in water.

[0023] The term "cross-link" means the formation of disulfide bonds between cysteine residues. A properly cross-linked proinsulin, insulin or insulin analog contains three disulfide bridges. The first disulfide bridge is formed between the cysteine residues at positions 6 and 11 of the A-chain. The second disulfide bridge links the cysteine residues at position 7 of the A-chain to the cysteine at position 7 of the B-chain. The third disulfide bridge links the cysteine at position 20 of the A-chain to the cysteine at position 19 of the B-chain.

[0024] Before the present invention, one skilled in the art selectively acylated the  $\epsilon$ -amino group by the use of a protecting group in a multi-step synthesis. Muranishi and Kiso, Japanese Patent Application 1-254,699, disclose a five-step synthesis for preparing acylated insulin derivatives. Likewise, Hashimoto et al., in *Pharmaceutical Research* 6: 171-176 (1989), teach a four step synthesis for preparing N-palmitoyl insulin. To selectively acylate the insulin, both references teach the use of the pMZ protecting group.

[0025] The present invention produces an N $\epsilon$ -acylated proinsulin, insulin, or insulin analog in a high yield, one step synthesis. The reaction permits the preparation of N $\epsilon$ -acylated proteins without the use of amino-protecting groups. The acylation is carried out by reacting an activated fatty acid ester with the  $\epsilon$ -amino group of the protein under basic conditions in a polar solvent. Under weakly basic conditions, all the free amino groups are not deprotonated and significant acylation of the N-terminal amino groups results. In an aqueous solvent or semi-aqueous solvent mixture, basic conditions means the reaction is carried out at a pH greater than 9.0. Because protein degradation results at a pH range exceeding 12.0, the pH of the reaction mixture is preferably pH 9.5 to 11.5, and most preferably 10.5. The pH measurement of the reaction mixture in a mixed organic and aqueous solvent is the pH of the aqueous phase prior to mixing.

[0026] The data in Table 1 demonstrates the effect of the basicity of the reaction on the selectivity of the reaction. The data presented in Table 1 was generated with human insulin acylated with two molar equivalents N-succinimidyl palmitate in 50 %  $CH_3CN$ /water.

Table 1:

Effects of pH on the acylation of Insulin			
Reaction products	Relative amount of product		
	pH 8.2	pH 9.5 10.2	pH
Human insulin	85.2 %	12.5 %	1.6 %
Mono-acylated A1 and B1	8.1%	0.3 %	0.4 %
Mono-acylated B29	5.2 %	70.2 %	79.6 %
Bis acylated	0.7 %	16.7 %	17.7 %
Ratio of Mono-acylated B29 to Mono-acylated A1 and B1	0.64	234	199
Table 1 demonstrates that the acylation of the $\epsilon$ -amino group is dependent on the basicity of the reaction. At a pH greater than 9.0, the reaction selectively acylates the $\epsilon$ -amino group of B29-lysine.			

[0027] In a non-aqueous solvent, the reaction is carried out in the presence of a base with basicity equivalent to a  $pK_a$  greater than or equal to 10.75 in water in order to sufficiently deprotonate the  $\epsilon$ -amino group(s). That is, the base must be at least as strong as triethylamine. Preferably, the base is tetramethylguanidine (TMG), diisopropylethylamine, or tetrabutylammonium hydroxide.

[0028] The choice of polar solvent is dependent largely on the solubility of the proinsulin, insulin, or insulin analog and the fatty acid ester. Most significantly, the solvent may be wholly organic. Generally acceptable organic solvents include DMSO, DMF and the like. Aqueous solvent and mixtures of aqueous and organic solvents are also operable. The selection of the polar solvents is limited only by the solubility of the reagents. Preferred solvents and solvent systems are DMSO; DMF; acetonitrile and water; acetone and water; ethanol and water; isopropyl alcohol and water; isopropyl alcohol, ethanol and water; and ethanol, propanol and water. Preferably, the solvent is acetonitrile and water; most preferably 50 % acetonitrile. One skilled in the art would recognize that other polar solvents are also operable.

[0029] The ratio of the reactants is not critical. Generally it is preferred that the activated fatty acid ester be in molar excess. Preferably the reaction is carried out with 1 to 4 molar equivalents, most preferably 1 to 2 molar equivalents,

of the ester. However, one skilled in the art would recognize that at very high levels of activated ester, bis or tri-acylated product will be produced in significant quantity.

[0030] The temperature of the reaction is not critical. The reaction is carried out at between 0 to 40 degrees Celsius and is generally complete in 15 minutes to 24 hours.

5 [0031] After acylation, the reaction is quenched, and the product is purified by standard methods such as reverse phase or hydrophobic chromatography. Thereafter, the product is recovered by standard methods such as freeze drying or crystallization.

[0032] Proinsulin, insulin and insulin analogs can be prepared by any of a variety of recognized peptide synthesis techniques including classical (solution) methods, solid phase methods, semi-synthetic methods, and more recent  
10 recombinant DNA methods. For example, Chance et al., U.S. patent application number 07/388,201, EPO publication number 383 472, Brange et al., EPO 214 826, and Belagaje et al., U.S. Patent 5,304,473 disclose the preparation of various proinsulin and insulin analogs and are herein incorporated by reference. The A and B chains of the insulin analogs of the present invention may also be prepared via a proinsulin-like precursor molecule using recombinant DNA techniques. See Frank et al., Peptides: Synthesis-Structure-Function, Proc. Seventh Am. Pept. Symp., Eds. D. Rich  
15 and E. Gross (1981) which is incorporated herein by reference.

[0033] The following examples are provided merely to further illustrate the invention. The scope of the invention is not construed as merely consisting of the following examples.

#### Example 1

20

##### Acylation of Insulin Using N-Succinimidyl Palmitate in DMSO

[0034] Biosynthetic Human Insulin (BHI) crystals (71.9 mg) were dissolved in 6.58 mL of DMSO. The solution was stirred at room temperature until the crystals were fully dissolved by visual inspection. A solution of activated ester (N-succinimidyl palmitate) was prepared by adding 20 mg of the solid activated ester to 2 mL of DMSO and vigorously  
25 stirring until all the activated ester particles were in solution by visual inspection. At that time, 1,1,3,3-Tetramethylguanidine (26.8  $\mu$ l) was added to 5 mL of the BHI solution, followed by DMSO (94.4 mL) and the previously prepared activated ester solution (400  $\mu$ l). The reaction was allowed to proceed at room temperature (20 to 25°C) for approximately 60 minutes. A sample was removed after 15 minutes, diluted 20-fold with 1 N acetic acid and analyzed by  
30 HPLC. The reaction yield calculated as the amount of B29-N<sup>6</sup>-Palmitoyl Human insulin in the quenched sample divided by the initial amount of BHI was 67.1%.

#### Example 2

35

##### Acylation of Insulin Using N-Succinimidyl Palmitate in Acetonitrile and Water

[0035] Biosynthetic Human Insulin (BHI) crystals (199.5 g) were dissolved in 20 L of 50 mM boric acid solution at pH 2.5. The pH of the solution was readjusted to 2.5 using 10% HCl, and the solution was stirred until the crystals were fully dissolved by visual inspection. A sample of the starting material was removed, and the absorbance measured at  
40 276 nm was 10.55. A solution of activated ester (N-Succinimidyl Palmitate) was prepared by adding 24 g of the solid activated ester to 2.4 L of acetonitrile pre-heated to approximately 50° C and vigorously stirring until all the activated ester particles were in solution by visual inspection. At that time, the pH of the BHI solution was adjusted to approximately 10.22 by the addition of 10% NaOH. Acetonitrile (18 L) was added to the pH adjusted BHI solution. The reaction was allowed to proceed at room temperature (20 to 25° C) for 110 minutes, then quenched by adding water (123 L)  
45 and adjusting the pH of the resulting diluted solution to 2.01 using 10% HCl and 10% NaOH. The reaction yield calculated as the amount of B29-N<sup>6</sup>-Palmitoyl Human insulin in the quenched reaction divided by the initial amount of BHI was 73%.

#### Example 3

50

##### Acylation of Lys<sup>B28</sup> Pro<sup>B29</sup>-Human Insulin Using N-Succinimidyl Palmitate in Acetonitrile and Water

[0036] Lys<sup>B28</sup>Pro<sup>B29</sup>-Human Insulin crystals (2.22 g) were dissolved in 100 mL of 50 mM boric acid solution at pH 2.5. The pH of the solution was readjusted to 2.5 using 10% HCl, and the solution was stirred until the crystals were  
55 fully dissolved by visual inspection. A solution of activated ester (N-Succinimidyl Palmitate) was prepared by adding 270 mg of the solid activated ester to 27 mL of acetonitrile pre-heated to approximately 50° C, and vigorously stirring until all the activated ester particles were in solution by visual inspection. The pH of the solution was adjusted to approximately 10.22 by the addition of 10% NaOH, and the solution was allowed to stir at 4°C for 15 minutes. Acetonitrile

## EP 1 227 107 A1

(73 mL) was added to the pH adjusted solution, followed by the previously prepared activated ester solution. The reaction was allowed to proceed at 4° C for 85 minutes, and was quenched by adding 1 N acetic acid (600 mL), resulting in a pH of 2.85. The reaction yield calculated as the amount of B28-N<sup>ε</sup>-Palmitoyl Lys<sup>B28</sup>Pro<sup>B29</sup>-human insulin in the quenched reaction divided by the initial amount of Lys<sup>B28</sup>Pro<sup>B29</sup>-human insulin was 72.5%.

### Example 4

#### Acylation of BHI Using N-Succinimidyl Palmitate in Acetonitrile and Water

- 10 **[0037]** Biosynthetic Human Insulin (BHI) crystals (3 g) were dissolved in 300 mL of 50 mM boric acid solution at pH 2.5. The pH of the solution was readjusted as necessary to 2.5 using 10% HCl and the solution was stirred until the crystals were fully dissolved by visual inspection. A solution of activated ester (N-Succinimidyl Palmitate) was prepared by adding 400 mg of the solid activated ester to 40 mL of acetonitrile and vigorously stirring. At that time, the pH of the BHI crystals solution was adjusted to approximately 10.2 by the addition of 10% NaOH. Acetonitrile (240 mL) was then
- 15 added to the BHI solution followed by the previously prepared activated ester solution. The reaction was allowed to proceed at room temperature (20 to 25° C) for approximately 90 minutes, then quenched by adding water (1800 mL) and adjusting the pH of the resulting diluted solution to approximately 2.5 using 10% HCl. The reaction yield calculated as the amount of B29-N<sup>ε</sup>-Palmitoyl Human insulin in the reaction divided by the initial amount of BHI was 75.7%.

### Example 5

#### Acylation of Proinsulin with N-Succinimidyl Palmitate in Acetonitrile and Water

- 25 **[0038]** Human Proinsulin (HPI) aqueous solution (28.2 mg/mL) was diluted with 50 mM boric acid to a final volume of 100 mL at 16.2 mg/mL HPI. The activated ester solution was prepared concurrently by dissolving 150 mg of N-succinimidyl palmitate in 15 mL acetonitrile (ACN) with rapid agitation. The pH of the HPI solution was then adjusted to 10.2 with 10% NaOH followed by the addition of 88 mL ACN. The reaction was initiated by addition of 12 mL activated ester solution (a 2x molar excess over HPI). The final reaction volume was 200 mL, 8 mg/mL HPI in 50% aqueous ACN. The reaction was allowed to proceed at room temperature (20 to 25°C) for approximately 60 minutes, then
- 30 quenched by adding an equivalent volume (200 mL) of 50 mM glycine, pH 10.0.
- [0039]** The exact ratios of ε-amino acylated species to α-amino acylated species were not calculated, the sum of all ε-amino acylated species within the chromatogram accounted for 87-90% of the total area, while the sum of all related substances (which would presumably include any α-amino acylated species) accounted for < 7% of the total area, for any given time point.

### Example 6

#### Acylation of Arg<sup>B31</sup>, Arg<sup>B32</sup> Human Insulin with Hexanoyl-N-Hydroxy-Succinimide Ester

- 40 **[0040]** Arg<sup>B31</sup>, Arg<sup>B32</sup> human insulin (1.3 mg) was dissolved in 200 μL of 200 mM (3-[Cyclohexylamino]-1-propanesulfonic acid) buffer at pH 10.4. Hexanoyl-N-hydroxy-succinimide ester (0.3 μMoles) dissolved in N,N-Dimethylformamide (DMF) was then added and stirred into solution. The reaction mixture was stirred at ambient temperature (20° to 25° C) for approximately four hours, then quenched by adjusting the pH to approximately 2.5 using 0.1 N HCl. Gelatinous particles were removed by passing the mixture through a 0.45 micron filter prior to HPLC analysis. Separation of the
- 45 titled product from starting material was achieved on a C<sub>4</sub> reverse phase analytical HPLC column. The reaction yield calculated as the amount of B29-N<sup>ε</sup>-hexanoyl-Arg<sup>B31</sup>, Arg<sup>B32</sup>-Human Insulin in the quenched reaction divided by the initial amount of Arg<sup>B31</sup>, Arg<sup>B32</sup>-Human Insulin was 69.4%.

### Example 7

#### Acylation of Leu<sup>B26</sup> Human Insulin with N-Succinimidyl Palmitate in DMSO

- 50 **[0041]** Leu<sup>B26</sup>-Human Insulin (1.0 mg) was dissolved in 1 mL of 95% Dimethyl Sulfoxide (DMSO), 5% Triethylamine (TEA). N-Succinimidyl palmitate (0.7 μMoles) dissolved in N,N-Dimethylformamide (DMF) was then added and stirred
- 55 into solution. The reaction mixture was stirred at ambient temperature (20° to 25° C) for approximately ninety minutes, then quenched by diluting the sample to 0.2 mg/mL with 0.1 N HCl. Gelatinous particles were removed by passing the mixture through a 0.45 micron filter prior to HPLC analysis. Separation of the titled product from starting material was achieved on a C<sub>4</sub> reverse phase analytical HPLC column. The reaction yield calculated as the amount of N<sup>ε</sup>-Palmitoyl-

Leu<sup>B26</sup>-Human Insulin in the quenched reaction divided by the initial amount of Leu<sup>B26</sup> Human Insulin was 36.4%.

#### Example 8

##### 5 Acylation of Human Insulin using N-succinimidyl palmitate in dimethylsulfoxide (DMSO)

[0042] A solution of insulin was prepared by dissolving Biosynthetic Human Insulin crystals (1 g, 0.17 mmol) completely in 20 mL DMSO at room temperature. At the same time, a solution of activated ester was prepared by dissolving N-succinimidyl palmitate (0.0817 g, 0.23 mmol) in 3 mL DMSO at 50°C. To the insulin solution, which was rigorously  
10 stirred, was added first 1,1,3,3-tetramethylguanidine (0.432 mL, 3.4 mmol) and then the entire solution of active ester. After 30 minutes, the reaction was quenched with 120 mL of 0.05 M HCl previously chilled to 0°C. The pH of the mixture was about 1.8. Analysis of the quenched mixture by reverse phase HPLC showed that B<sup>29</sup>-N<sup>ε</sup>-palmitoyl insulin accounted for 72.2% of the total protein eluted, and represented 95% of all mono-acylated insulin.

[0043] The entire reaction mixture was loaded on a Vydac C4 preparative reverse phase column (5x25 cm) previously  
15 equilibrated with a solvent mixture containing 0.1% trifluoroacetic acid, 20% acetonitrile in water. After loading, the column was first washed with 500 mL of the same solvent, and then developed at a flow rate of 4 mL/minutes and with a solvent system consisting of 0.1% trifluoroacetic acid, acetonitrile and water, wherein the acetonitrile concentration increased from 20 to 80% within 9 L. B<sup>29</sup>-N<sup>ε</sup>-palmitoyl insulin eluted at this solvent system composing of approximately 53% acetonitrile. After removal of the solvent by lyophilization the yield of N<sup>ε</sup>-palmitoyl insulin was 414 mg (0.0684  
20 mmol) or 40.2% based on starting material.

#### Example 9

##### 25 Acylation of Lys<sup>B28</sup>Pro<sup>B29</sup>-human insulin with 1-octanoyl-N-hydroxysuccinimide ester

[0044] Lys(B28), Pro(B29) Human Insulin (KPB) crystals (2.0 g) were dissolved in 200 mL of 50 mM boric acid buffer at pH 2.5. The pH of the solution was readjusted to 2.5 using 10% HCl, and the solution was stirred until the crystals were fully dissolved by visual inspection. A solution of activated ester (1-octanoyl-N-hydroxysuccinimide ester) was prepared by adding 175 mg of the solid activated ester to 25.62 mL of acetonitrile, and vigorously stirring until all the  
30 activated ester particles were in solution by visual inspection. The pH of the KPB solution was adjusted to approximately 10.4 by the addition of 10% NaOH, and the solution was allowed to stir at ambient temperature for about 5 minutes. Acetonitrile (176 mL) was added to the pH-adjusted KPB solution, followed by addition of the previously prepared activated ester solution. The reaction was allowed to proceed at ambient temperature for 90 minutes, and was quenched by adding 5.5 mL of 10% HCl (2.75% v/v) and three volumes (1200 mL) of cold dH<sub>2</sub>O, resulting in a final pH of 2.70.  
35 The reaction yield, calculated as the amount of LysB29(C8)KPB in the quenched reaction divided by the initial amount of BHI, was 75.5%. This solution was divided into two 800 mL aliquots for purification by hydrophobic chromatography (SP20SS). Column chromatography was followed by ultrafiltration and lyophilization

[0045] The data in Table 2 demonstrates the selective acylation of insulin, insulin analogs and proinsulin. The experiments were carried out at room temperature with N-hydroxy-succinimide esters of the fatty acid. In the following  
40 Table, TMG and TEA represent tetramethylguanidine and triethylamine respectively. ND indicates no data are available.

45

50

55

Table 2

Solvent	Ratio Solvent /H <sub>2</sub> O	Protein	Fatty acid	pH	% Mono- Acylated (A1 and B1)	% Mono- Acylated (B29)	% Bis- Acylated	Ratio monoacyl- B29 to monoacyl- A1 and B1
DMSO	100/0	Insulin	C16	TMG	<0.1	70.7	29.3	>700
DMF	100/0	Insulin	C16	TMG	0.2	71.7	15.3	359
Acetonitrile	50/50	Insulin	C16	10.2	1.2	79.9	14.3	67
Acetone	50/50	Insulin	C16	10.2	1.1	70.8	11.8	64
Ethanol	50/50	Insulin	C16	10.2	1.6	45.6	1.9	29
IPA	50/50	Insulin	C16	10.2	1.9	66.4	6.9	35
Ethanol/IPA	50/50	Insulin	C16	10.2	1.8	50.3	2.8	28
Ethanol/n- propanol	50/50	Insulin	C16	10.2	2.6	49.5	2.75	19
Acetonitrile	50/50	Insulin	C6	10.2	0.48	80.6	17.7	167
Acetonitrile	50/50	Insulin	C8	10.2	0.37	81.4	17.1	219
Acetonitrile	50/50	Insulin	C10	10.2	0.10	83.4	14.4	834
Acetonitrile	50/50	Insulin	C12	10.2	0.26	82.7	15.0	320
Water	100	ArgB31, ArgB32 -Insulin	C6	10.4	<0.1	69.4	ND	>700
DMF	60/40	Insulin	Oleic	10.4	1.1	16	ND	14
DMF	60/40	Insulin	C14	10.4	3.5	47.4	ND	14
DMF	80/10	Insulin	C18	TEA	8.7	59.1	ND	7
DMF	80/10	des(64,65) proinsulin	C16	TEA	5.6	31.2	ND	6
DMSO	95/05	LeuB26- Insulin	C16	TEA	5.8	36.4	ND	6.3

## Claims

1. A process for selectively acylating a free ε-amino group of proinsulin, insulin, or an insulin analog also having a free α-amino group, comprising carrying out the selective acylation in a polar solvent, and under basic conditions so that the free amino groups are substantially deprotonated.



2. The process of Claim 1 wherein the basic conditions are at pH of 9.0 or greater.
3. The process of Claims 1-2 wherein the pH is greater than 9.0.
- 5 4. The process of Claims 1-2 wherein the basic conditions are at a pH of greater than 9.0 if the polar solvent is an aqueous or semi-aqueous organic solvent, or if the polar solvent is a non-aqueous organic solvent, the selective acylation is carried out in the presence of a base with basicity equivalent to a  $pK_a$  greater than or equal to 10.75 in water.
- 10 5. The process of Claims 1-4 wherein the proinsulin, insulin, or insulin analog is selectively acylated with a fatty acid.
6. The process of Claims 1-5 wherein the proinsulin, insulin, or insulin analog is human insulin, an insulin analog, or Lys<sup>B28</sup>Pro<sup>B29</sup>-human insulin.
- 15 7. The process of Claim 1-6 wherein the proinsulin, insulin, or insulin analog is selectively acylated by a soluble activated fatty acid ester.
8. The process of Claim 7 wherein the soluble activated fatty acid ester is a N-hydroxysuccinimide ester of a C<sub>6</sub> to C<sub>18</sub> fatty acid.
- 20 9. The process of Claims 7-8 wherein the soluble activated fatty acid ester is a N-hydroxysuccinimide ester of palmitic acid.
10. The process of Claim 5 wherein the fatty acid is a C18 fatty acid.
- 25 11. The process of Claim 5 wherein the fatty acid is a C14 fatty acid.
12. A process of selectively acylating proinsulin, insulin, or an insulin analog having a free  $\epsilon$ -amino group and a free  $\alpha$ -amino group with a fatty acid, which comprises reacting the  $\epsilon$ -amino group with a soluble activated fatty acid ester under basic conditions in a polar solvent.
- 30 13. The process of Claim 12 wherein the protein is human insulin, an insulin analog, or Lys<sup>B28</sup>Pro<sup>B29</sup>-human insulin.
14. The process of Claim 12 wherein the activated fatty acid ester is a N-hydroxysuccinimide ester of a C<sub>6</sub> to C<sub>18</sub> fatty acid.
- 35 15. The process of Claim 12 wherein the activated fatty acid ester is a N-hydroxysuccinimide ester of a C<sub>14</sub> to C<sub>18</sub> fatty acid.
- 40 16. The process of any one of Claims 12 to 15 wherein the activated fatty acid ester is a N-hydroxysuccinimide ester of palmitic acid.
17. A process of selectively acylating proinsulin, insulin, or an insulin analog having a free  $\epsilon$ -amino group and a free  $\alpha$ -amino group with a fatty acid, which comprises reacting the  $\epsilon$ -amino group with a soluble activated fatty acid ester in a semi-aqueous solvent at a pH from about 9.0 to 12.0.
- 45 18. The process of Claim 17, wherein the protein is human insulin, an insulin analog, or Lys<sup>B28</sup>Pro<sup>B29</sup>-human insulin.
19. The process of Claim 18, wherein the pH is from about 9.5 to about 10.5.
- 50 20. The process of Claim 19, wherein the semi-aqueous solvent is acetonitrile and water.
21. The process of Claim 20, wherein the solvent is 50% acetonitrile.
- 55 22. The process of Claim 21, wherein the fatty acid ester is N-succinimidyl palmitate, N-succinimidyl octanoate, or N-succinimidyl myristate.



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 02 00 0258

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
E	DE 44 37 604 A (BASF AG) 25 April 1996 (1996-04-25) * page 7, line 60 - page 8, line 16; claims; examples 1-3 *	1,5-19, 22	C07K14/62
P,X	WO 95 07931 A (NOVONORDISK AS ; HAVELUND SVEND (DK); HALSTROEM JOHN BROBERG (DK);) 23 March 1995 (1995-03-23) * page 11, line 3 - line 13; claims; examples *	1,5-19, 22	
D,X	DATABASE WPI Section Ch, Week 8947 Derwent Publications Ltd., London, GB; Class B04, AN 89-343268 XP002050608 & JP 01 254699 A (KODAMA KK), 11 October 1989 (1989-10-11) * abstract *	1,5-19, 22	
D,X	M. HASHIMOTO ET AL.: "Synthesis of Palmitoyl Derivatives on Insulin and Their Biological Activities" PHARMACEUTICAL RESEARCH, vol. 6, no. 2, February 1989 (1989-02), pages 171-176, XP002050607 * page 172 * * page 174, right-hand column, last paragraph - page 176, left-hand column, paragraph 1 *	1,5-19, 22	TECHNICAL FIELDS SEARCHED (Int.Cl.7) C07K
X	US 3 471 464 A (THUONG TRUONG VAN ET AL) 7 October 1969 (1969-10-07) * column 3, line 27 - column 41 * * column 4, line 1 - column 25; claims; example 3 *	1,6	
-/--			
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 3 June 2002	Examiner Fuhr, C
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date O : document cited in the application I : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			

EP 02 00 0258 (P4C21)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 02 00 0258

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	GB 1 381 273 A (NAT RES DEV) 22 January 1975 (1975-01-22) * claims; example 3; table *	1,6	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 3 June 2002	Examiner Fuhr, C
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone  Y : particularly relevant if combined with another document of the same category  A : technological background  O : non-written disclosure  P : intermediate document</p> <p>T : theory or principle underlying the invention  E : earlier patent document, but published on, or after the filing date  D : document cited in the application  I : document cited for other reasons  % : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03/82 (P04001)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 00 0258

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

03-06-2002

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
DE 4437604	A	25-04-1996	DE 4437604 A1	25-04-1996
			WO 9612505 A1	02-05-1996
WO 9507931	A	23-03-1995	AT 204882 T	15-09-2001
			AU 4846197 A	19-02-1998
			AU 682061 B2	18-09-1997
			AU 7652094 A	03-04-1995
			BG 61611 B1	30-01-1998
			BG 100420 A	31-12-1996
			BR 9407508 A	07-01-1997
			CA 2171424 A1	23-03-1995
			CN 1133598 A , B	16-10-1996
			CZ 9600789 A3	16-10-1996
			DE 69428134 D1	04-10-2001
			DE 69428134 T2	02-05-2002
			WO 9507931 A1	23-03-1995
			DK 792290 T3	01-10-2001
			EP 1132404 A2	12-09-2001
			EP 0792290 A1	03-09-1997
			ES 2163451 T3	01-02-2002
			FI 961220 A	14-05-1996
			HU 75991 A2	28-05-1997
			IL 110977 A	29-06-2000
			JP 2000060556 A	29-02-2000
			JP 3014764 B2	28-02-2000
			JP 9502867 T	25-03-1997
			NO 961070 A	15-05-1996
			NZ 273285 A	24-10-1997
			PL 313444 A1	08-07-1996
			PT 792290 T	30-01-2002
			RO 112873 B1	30-01-1998
			RU 2164520 C2	27-03-2001
			SI 792290 T1	31-12-2001
			SK 32496 A3	06-11-1996
			US 5750497 A	12-05-1998
			US 6011007 A	04-01-2000
			ZA 9407187 A	17-03-1995
JP 1254699	A	11-10-1989	NONE	
US 3471464	A	07-10-1969	FR 1468831 A	10-02-1967
			BE 694334 A	31-07-1967
			DE 1543837 A1	02-01-1970
			DK 119831 B	01-03-1971
			GB 1157528 A	09-07-1969
			SE 322526 B	13-04-1970

EPO FORM 1005S

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 00 0258

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

03-06-2002

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
GB 1381273	A	22-01-1975	AU 472582 B	27-05-1976
			AU 3821372 A	26-07-1973
			BE 778538 A1	26-07-1972
			CA 980765 A1	30-12-1975
			CH 547777 A	11-04-1974
			DE 2204053 A1	17-08-1972
			FR 2123524 A5	08-09-1972
			IE 36225 B1	15-09-1976
			NL 7201179 A	01-08-1972
			SE 382452 B	02-02-1976
			US 3868357 A	25-02-1975
			ZA 7200277 A	27-09-1972

EPO FORM P0159

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82